Discussion and conclusions: There was no significant
reduction in motor cortical glial activation following 12–24
weeks of Ibudilast treatment in ALS, as measured by PBR-
PET SUVR. Final clinical trial results including clinical and
biofluid biomarker results will be available at the time of
final presentation during MND Symposium 2019.
>>13443
12月の発表
Discussion and conclusions: There was no significant
reduction in motor cortical glial activation following 12–24
weeks of Ibudilast treatment in ALS, as measured by PBR-
PET SUVR. Final clinical trial results including clinical and
biofluid biomarker results will be available at the time of
final presentation during MND Symposium 2019.